Experientia

, Volume 51, Issue 9–10, pp 927–935 | Cite as

Effect of Royal Jelly on serum lipids in experimental animals and humans with atherosclerosis

  • J. Vittek
Reviews

Abstract

The primary objective of this review was to assess the size and consistency of Royal Jelly (RJ) effect on serum lipids in experimental animals and humans. The data from animal studies were pooled, where possible, and statistically evaluated by Student's t-test. Meta-analysis was used for the evaluation of human trials. It was found that RJ significantly decreased serum and liver total lipids and cholesterol levels in rats and rabbits and also retarded the formation of atheromas in the aorta of rabbits fed a hyperlipemic diet. Meta-analysis of the controlled human trials of RJ to reduce hyperlipidemia showed a significant reduction in total serum lipids and cholesterol levels and normalization of HDL and LDL as determined from decrease in β/α lipoproteins. The best available evidence suggests that RJ at approximately 50 to 100 mg per day, decreased total serum cholesterol levels by about 14%, and total serum lipids by about 10% in the group of patients studied.

Key Words

Royal Jelly serum lipids serum cholesterol atherosclerosis humans rat rabbit 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Anitschnikow, N. N., A history of experimentation on arterial atherosclerosis in animals, in: Arteriosclerosis, pp. 21–44. Ed. E. V. Cowdry. Charles C. Thomas, Springfield, Illinois 1967.Google Scholar
  2. 2.
    Anitschnikow, N. N., Experimental arteriosclerosis in animals, in: arteriosclerosis a Survey of the Problem, pp. 271–322. Ed. E. V. Cowdry. Mac Millan, New York 1967.Google Scholar
  3. 3.
    Armstrong, M. L., Regression of atherosclerosis. Atheroscl. Rev.1 (1976) 137–82.Google Scholar
  4. 4.
    Bechteeva, T. T., Treatment of stenocardia with royal jelly. Inf. Bjul. o Mat. Mol.3 (1962) 109.Google Scholar
  5. 5.
    Belong, R. P., and Masek, J. A., The effect of royal jelly of bees for treatment of cerebral atherosclerosis. Vrach. Delo8 (1971) 26–28.PubMedGoogle Scholar
  6. 6.
    Beselkoev, T. I., Pathol. fiziologia Serd.-sosud. syst. p 211. Tbilisi 1964.Google Scholar
  7. 7.
    Brown, G., Albers, J. J., Fisher, L. D., et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N. Engl. J. Med.323 (1990) 1289–98.PubMedGoogle Scholar
  8. 8.
    Butcher, R. W., and Baird, C., Effect of lipolytic and antilipolytic substances on adenosine 3′,5′-monophosphate levels in isolated fat cells. J. biol. Chem.243 (1968) 1705–12.PubMedGoogle Scholar
  9. 9.
    DeCarli, H. O., Cornejo, L. G., Castelletto, R., et al. Acción de la jelea real, piridinol carbamate y heparinoides sinteticos sobre la aterosclerosis experimental. Prensa méd. argent.59 (1972) 916–23.Google Scholar
  10. 10.
    Fosati, C., Sulle possibilita terapeutiche della ‘Gelatina reale’. Clinica terap.62 (1972) 377–87.Google Scholar
  11. 11.
    Greengard, P., The vitamins, in: Pharmacological Basis of Therapeutics, pp. 1643–1646. Eds. L. S. Goodman and D. Gillman. Collier-Mac Millan Canada Ltd, Toronto 1970.Google Scholar
  12. 12.
    Hammerl, H., and Pichler, O., Untersuchungen über die Wirkung des Weiselfuttersaftes auf den alternden Menschen unter besonderer Berücksichtigung des Cholesterin-Stoffwechsels. Int. J. prohyl. Med. SocHyg./Wien2 (1958) 69–71.Google Scholar
  13. 13.
    Hammerl, H., and Pichler, O., Zur Therapie mit Apifortyl. Medsche Klin.45 (1960) 2015–21.Google Scholar
  14. 14.
    Hammerl, H., and Pichler, O., Vorläufiger Bericht über die Behandlung der Arteriosclerose mit Gelee Royale-Holzinger. Z. Med.13/14 (1957) 364.Google Scholar
  15. 15.
    Hanza, S. M., Aod El-Wahab, S. M., Shehata, M. M., and Mohamed, T. R., Investigation of Royal Jelly Part I: Vitamin content of Royal Jelly and effect on hepatic vitamin level in male and female rats. Egypt. J. pharm. Sci.20 (1979) 365–373.Google Scholar
  16. 16.
    Hiyamuta, K., Toshima, H., Koga, Y., et al., Relationship between coronary risk factors and arterographic feature of coronary atherosclerosis. Jap. Circul. J.54 (1990) 442–47.Google Scholar
  17. 17.
    Hove, S. R., Dimick, P. S., and Benton, A. W., Composition of freshly harvested and commercial Royal Jelly. J. apic. Res.24 (1985) 52–61.Google Scholar
  18. 18.
    Illingworth, D. R., and Schmidt, E. B., The influence of dietary n-3 fatty acids on plasma lipids and lipoproteins. Ann. N.Y. Acad. Sci.676 (1993) 60–69.PubMedGoogle Scholar
  19. 19.
    Ingelfinger, J. A., Mosteller, F., Thibodean, L. A., and Ware, J. H., Biostatistics in Clinical Medicine, McGraw Hill Inc., New York 1994.Google Scholar
  20. 20.
    Jacoli, G., and Nobili, F., Ricerche su un principo ad azione parasimpaticomimetica della Gelatina Reale. Quad. Nutr.17 (1957) 91.Google Scholar
  21. 21.
    Kaczor, M., Koltek, A., and Matuszewski, J., The effect of Royal Jelly on blood lipids in atheromatic subjects. Polski Tygod. lek.17 (1962) 140–44.Google Scholar
  22. 22.
    Kadyseva, N., The use of Royal Jelly for treatment of various clinical forms of atherosclerosis. Inf. Bjul. o Mat. Mol.3 (1962) 90.Google Scholar
  23. 23.
    Kalinin, A. P., Effect of royal jelly and bee venom on some endocrine glands. Problem Endokr. Gormonoter.8 (1962) 119–123.Google Scholar
  24. 24.
    Lecker, G., Capella, P., Conte, L. S., Ruini, F., and Giordani, G., Components of Royal Jelly II. The lipid fracion, hydrocarbons and sterols. J. apic. Res.21 (1982) 178–184.Google Scholar
  25. 25.
    Ling, S. S., Zhou, H. P., Tang, C. P., Gzy Tian and Sun, W. L., The physiological disposotion of 10-hydroxydecenoic acid (10 HDA) in rats and mice. Acta. pharmac. sin.21 (1982) 115–121.Google Scholar
  26. 26.
    Loscalzo, J., Regression of coronary atherosclerosis. Science323 (1990) 1337–39.Google Scholar
  27. 27.
    Lupachev, V. F., K. farmakologii Apilaka. Farmak. Toks.26 (1963) 333–8.Google Scholar
  28. 28.
    Mach, W. J., Hodis, H. N., and Blankenhorn, D. H., Regression of atherosclerosis: A report from two clinical trials. Atheroscl. Rev.25 (1993) 301–9.Google Scholar
  29. 29.
    Madar, J., Maly, E., Neubauer, A., Nicak, A., Zapaticka, J., and Kocis, J., Einfluss des Mutterbreies der Bienen (Gelee Royale) und des Heparins auf die experimentelle Atherosklerose der Kaninchen. Z. Altersforsch.18 (1965) 109–14.Google Scholar
  30. 30.
    Madar, J., Maly, E., Neubauer, E., and Moscovic, F., Einfluss des Bienenmutterbreies (Gelée Royale) auf den Cholesterolspiegel auf die Totallipide im Serum und auf die fibrinolytische Aktivität des Plasmas der an Atherosklerose leidenden älteren Menschen. Z. Altersforsch.18 (1965) 103–8.Google Scholar
  31. 31.
    Meada, T., Kurota, H., and Motoyoshi, K., Effect of Royal Jelly and 10-hydroxy decenoic acid on the sebaceous glands of hamsters. Nippon Gakkai Zasshi98 (1988) 469–475.Google Scholar
  32. 32.
    Makarova, V. G., The effect of course-vise administration of different doses of Apilak upon some lipid metabolism indices. Farmak. Toks.32 (1969) 63–5.Google Scholar
  33. 33.
    Marmot, M. G., Hypercholesteremia a public, health problem, Atheroscler. Rev.18 (1988) 95–108.Google Scholar
  34. 34.
    Matuszewski, J., and Kaczor, M., Effect of Royal Jelly on mammals. Acta. physiol. pol.5 (1961) 745.Google Scholar
  35. 35.
    Mishenko, E. D., The use of Royal Jelly preparation in therapy of some cardiovascular diseases, in: Serd. Sosud. Zabolevanija i bolezni obmena vescestv, p. 63. Nauka, Moskva 1964.Google Scholar
  36. 36.
    Mormone, V., and Nunziata, B., in: L'action de al Gelee Royale sur animaux superieurs et sur l'Home. Annls Abeille3 (1959) 223.Google Scholar
  37. 37.
    Mullen, B., and Rosenthal, R., Basic Meta-analysis: Procedures and Programs. Lawrence Erlbaum Assoc., Hillsdal, New Jersey 1985.Google Scholar
  38. 38.
    Nakajin, S., Okiyama, K., Yamashita, S., Akiama, Y., and Shinoda, M., Effect of royal jelly on experimental hypercholesteremia in rabbits. Shoyakugaku Zasshi36 (1982) 65–69.Google Scholar
  39. 39.
    Nemanova, S. B., Treatment of stenocardia with royal jelly, p. 13. Inf. Bjul. o Mat. Mol. I, Rjazan1 (1959) 13.Google Scholar
  40. 40.
    O'Brien, K. D., Xue-Qiao, Zhao, Albers, J. J., and Brown, B. G., A review of the familial atherosclerosis treatment study: Implications for the regression of coronary atherosclerosis and prevention of clinical cardiovascular events. Atheroscl. Rev.25 (1993) 311–19.Google Scholar
  41. 41.
    Ornish, D., Regression of coronary artery disease by a multifactorial approach: The lifestyle heart trial. Atheroscl. Rev.25 (1993) 319–29.Google Scholar
  42. 42.
    Pavero, A., and Caviglia, E., La pappa reale e la sua applicazione in terapia. Arch. E Maragliano di Path. e Clin.13 (1957) 1023–33.Google Scholar
  43. 43.
    Pejcev, P., Chadzijev, V., Nikiforov, N., et al. Results of the combined use of some bee products, honey, royal jelly and pollen to geriatric patients. Folia med. Plovdiv8 (1966) 329–33.PubMedGoogle Scholar
  44. 44.
    Pejcev, P., Beleva-Stapkova, R., and Atanasov, N., Effect of Royal Jelly on utilization of oxygen and adenosinetriphosphatase activity in the tissues of albino rats. 25 Int. Congr. Apimonia, 8–14 Sept. 1975, pp. 178–184. Grenoble, France 1975.Google Scholar
  45. 45.
    Pichler, P., Zur Therapie mit Apifortyl. Medsche Klin.45 (1960) 2015.Google Scholar
  46. 46.
    Ross, R., Hyperlipidemia and atherosclerosis. Science193 (1976) 1094–1100.PubMedGoogle Scholar
  47. 47.
    Ross, R., Cellular mechanism of atherosclerosis. Atheroscl. Rev.25 (1993) 195–200.Google Scholar
  48. 48.
    Russ, E. M., Eder, H. A., and Barr, D. P., Protein lipid relationship in human plasma. I. In normal individuals. Am. J. Med.11 (1951) 468–479.PubMedGoogle Scholar
  49. 49.
    Sasko, E., and Vittek, J., A short review of the composition, chronological activity and clinical use of royal jelly an active ingredient of Viat-Apinol Spofa. Farmakoter. Zpr. Spofa11 (1965) 413–428.Google Scholar
  50. 50.
    Schaefer, E. J., Lipid lowering agents other than anion exchange resins which affect the gastrointestinal system, in: Pharmacologic Control of Hyperlipidemia, pp. 119–132. Eds R. Fears, R. I. Levy, J. Shepherd, C. J. Packard, and N. E. Miller. Prons. Sci. Publisher, Barcelona 1986.Google Scholar
  51. 51.
    Schuel, R. W., and Dixon, S. E., A possible role of 10-hydroxydecenoic acid in the sterol nutrition of the larval honey bee. J. Apic. Res.21 (1982) 115–121.Google Scholar
  52. 52.
    Seidel, D., Significance of risk factors. Atheroscl. Rev.25 (1993) 293–99.Google Scholar
  53. 53.
    Shepherd, J., Packard, C. J., Pharmacologic control of plasma cholesterol: Mechanism of action of hypocholesterolemic agents. Atheroscl. Rev.18 (1988) 109–21.Google Scholar
  54. 54.
    Shinoda, J., Nakajin, S., Oikawa, T., et al., Biochemical studies on vasoactive factor in royal jelly. Yakugaku Zasshi98 (1978) 132–45.Google Scholar
  55. 55.
    Shinoda, M., Taguchi, M., Okiyama, K., et al. Gas chromatographic determination of royal jelly content in various pharmaceutical preparations. Shoyakugaku Zasshi36 (1982) 315–18.Google Scholar
  56. 56.
    Sitár, J., and Černochová, Z., Treatment of angina pectoris with Vita-Apinol Spofa. Some metabolic effects of the drug. Vnitr. lek.14 (1967) 1798–1805.Google Scholar
  57. 57.
    Svoboda, J. A., Herbert, E. W., and Thompson, M. J., Sterols of organs involved in brood food production and of Royal Jelly in honey bees. Insect. Biochem.16 (1986) 479–482.Google Scholar
  58. 58.
    Takahashi, K., Kiuchi, K., Endo, M., Furuno, Y., Shinozuka, T., and Hasegawa, S., Fractions actives de la gelee royale. C. r. Séan. Soc. Biol.157 (1963) 428–430.Google Scholar
  59. 59.
    Taylor, C. B., Patton, D. E., and Cox, G. E., Atherosclerosis in rhesus monkeys. VI. Fatal myocardial infarction in a monkey fed fat and cholesterol. Archs Pathol.76 (1963) 404–12.Google Scholar
  60. 60.
    Taylor, C. B., Manalo-Esterlla, P., and Cox, G. E., Atherosclerosis in rhesus monkeys. V. marked diet-induced hypercholesteremia with xanthomatosis and severe atherosclerosis. Archs Pathol.76 (1963) 239–49.Google Scholar
  61. 61.
    Vergoesen, A. J., Hypothesis of interactions between acetylcholine and Prostaglandin biosynthesis. Nutr. Brain5 (1979) 109.Google Scholar
  62. 62.
    Vinogradova, T. V., and Zajcev, G. P., Pcela i zdorovie celoveka (Bee and the health of man), Roselschozizdat, Moskva 1964.Google Scholar
  63. 63.
    Vittek, J., and Slomiany, Testosterone in royal jelly. Experientia40 (1984) 104–6.Google Scholar
  64. 64.
    Vittek, J., and Kresanek, J., A contribution to chemical investigation of royal jelly and possibilities of applying it in therapy. Acta pharm. Pharmac., Bohemoslov.10 (1965) 83–125.Google Scholar
  65. 65.
    Vittek, J., Effect of royal jelly on cardiovascular and respiratory systems, in: Vcelia materska kasicka (Royal jelly), pp. 257–264. Eds J. Vittek and J. Janci, SPVL, Bratislava 1968.Google Scholar
  66. 66.
    Vittek, J., and Sasko, E., Vita Apinol (Gelee Royale) Farmakoterap. zpravy, Spofa Suppl.2 1966.Google Scholar
  67. 67.
    Yamamura, T., Tajima, S., Miyake, Y., Nomura, S., Yamamoto, A., Haze, K., and Hiramori, K., Hyperlipoproteinemia as a risk factor for ischemic heart disease. Jap. Circul. J.54 (1990) 448–456.Google Scholar
  68. 68.
    Zaicev, G., and Poriadin, V., The use of royal jelly in the treatment of endarteritis and atherosclerosis of peripheral arteries of extremities. Inf. Bjul o Mat. Mol. III, Rjazan3 (1962) 62.Google Scholar

Copyright information

© Birkhäuser Verlag Basel 1995

Authors and Affiliations

  • J. Vittek
    • 1
  1. 1.Department of Medicine, Section of Endocrinology and MetabolismNew York Medical CollegeValhallaUSA

Personalised recommendations